The reason for a number of recent Neurontin lawsuits has been the revelation that drug's manufacturers illegally marketed Neurontin for non-FDA approved uses (called “off-label” uses), and paid physicians thousands of dollars to recommend the drug based on faulty or non-existant drug trial results. In recent disclosures related to Neurontin lawsuits, current drug manufacturer Pfizer has admitted that non-approved uses account for around 80% of Neurontin prescriptions.
Many Neurontin lawsuits were filed on behalf of patients who were prescribed Neurontin for conditions such as bipolar disorder, drug and alcohol withdrawal, attention deficit disorder, and other conditions for which the FDA had not approved the use of Neurontin. Neurontin lawsuits may also be filed if patients suffered from Neurontin side effects, especially if they were not sufficiently advised of such complications.
May 13, 2003 - NY Times
Court Papers Suggest Scale of Drug's Use
May 13, 2003- Press Release
Settlement: Fifty Attorneys General Announce Settlement with Pfizer Over Improper Off-Label Drug Marketing
